Condition

Non Small Cell Lung Cancer Metastatic clinical trials and research

• 16Clinical trials
• 30Countries

Newest Non Small Cell Lung Cancer Metastatic clinical trials

All recruiting trials (16)

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

• OM-RCA-01 (anti-FGFR1 antibody) for metastatic tumors that express FGFR1

  This trial will try OM-RCA-01, an IV antibody given every two weeks, in adults with metastatic cancers whose tumors test positive for FGFR1 and who have progressed after standard treatments.

  Recruiting at 4 sites Phase 1/2 Kidney Cancer Research Bureau · Kazan' and 4 other locations · NCT07292168

• Proteomic-guided, risk-adapted therapy for advanced non-small cell lung cancer

  This trial tests whether using a proteomic test plus a toxicity risk tool to pick immune checkpoint inhibitor–based treatment can improve 12-month progression-free survival for people with previously untreated advanced non-small cell lung cancer.

  Recruiting at 4 sites Phase 2 University of California, Davis · Chico, California and 3 other locations · NCT07250477

• First-line nivolumab plus ipilimumab with short-course chemotherapy for metastatic non-small cell lung cancer

  This project will collect real-world data to see if nivolumab plus ipilimumab combined with a short course of platinum chemotherapy works well as first-line treatment for adults with metastatic non-small cell lung cancer who do not have EGFR or ALK alterations.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07190677

• PF-08046054 (SGN-PDL1V) versus docetaxel for PD-L1–positive advanced non-small cell lung cancer

  This test compares PF-08046054 (SGN-PDL1V) with docetaxel for adults whose PD-L1–positive advanced NSCLC progressed after PD-1/PD-L1 inhibitors, platinum chemotherapy, and targeted treatments when appropriate.

  Recruiting at 454 sites Phase 3 Pfizer · Alabaster, Alabama and 468 other locations · NCT07144280

• Cemiplimab guided by ctDNA levels (PALACE)

  This study will see if starting adults with advanced (stage IIIB/C or IV) non-small cell lung cancer and PD-L1 ≥50% on cemiplimab, then using ctDNA and early scans to decide whether to add chemotherapy, can improve overall survival.

  Recruiting at 19 sites Phase 2 Fundación GECP · Alicante, Alicante and 19 other locations · NCT06917573

• Treating brain metastasis in lung cancer with radiosurgery and osimertinib

  This study is testing if adding a special type of radiation therapy to the lung cancer drug osimertinib can help people with brain metastases feel better and improve their treatment results.

  Recruiting at 8 sites Phase 2 Memorial Sloan Kettering Cancer Center · Miami, Florida and 7 other locations · NCT06741085

• Combining Befotertinib and Icotinib for treating specific lung cancer mutations

  This study is testing if combining two targeted lung cancer treatments, Befotertinib and Icotinib, can help patients with specific EGFR mutations in Non-Small Cell Lung Cancer feel better and improve their outcomes.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06517953

• Using patients' own immune cells to treat advanced lung cancer

  This study is testing if using patients' own immune cells can help people with advanced lung cancer that hasn't responded to other treatments.

  Recruiting Phase 1 Shanghai Juncell Therapeutics · Shanghai · NCT06473961

• Combining chemotherapy with Lorlatinib for ALK positive lung cancer

  This study is testing if combining chemotherapy with Lorlatinib can help people with ALK positive lung cancer who have seen their disease get worse while on Lorlatinib.

  Recruiting Phase 2 Centro di Riferimento Oncologico - Aviano · Aviano and 8 other locations · NCT06378892

• Adding tepotinib to lazertinib for EGFR‑mutant metastatic lung cancer with MET overexpression or amplification after progression on lazertinib

  This trial tests whether adding the MET blocker tepotinib to lazertinib helps people with EGFR‑mutant metastatic non‑small cell lung cancer whose tumors show MET overexpression or amplification and who have progressed on lazertinib.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gangnam-gu · NCT06106802

• Monitoring treatment in advanced lung cancer using liquid biopsy

  This study is testing if a blood test can help doctors better track treatment progress in people with advanced lung cancer who are receiving immunotherapy, compared to regular scans.

  Recruiting at 3 sites Zealand University Hospital · Hillerød, Region H and 4 other locations · NCT05889247

• Screening MRI for brain disease in advanced lung cancer patients

  This study tests whether MRI scans of the brain can help find hidden brain cancer in patients with advanced lung cancer who don’t have any symptoms.

  Recruiting at 3 sites University Medical Center Groningen · Groningen, Provincie Groningen and 2 other locations · NCT05864794

• Treatment for brain metastases in lung cancer patients with EGFR mutations

  This study is testing if a new drug called armatinib, alone or with targeted radiation therapy, can help lung cancer patients with brain metastases feel better and manage their symptoms.

  Recruiting Phase 3 Shanghai Cancer Hospital, China · Shanghai, Shanghai Municipality · NCT05800223

• Targeted radiation therapy for advanced lung cancer

  This study is testing if adding a special type of radiation therapy to regular drug treatment can help people with advanced lung cancer that has spread to the liver feel better and live longer.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Miami, Florida and 8 other locations · NCT05657873

• Platform for assessing molecular testing and treatment outcomes in lung cancer patients

  This study is trying to gather and analyze information about treatments and outcomes for people with lung cancer to improve care and understand their quality of life better.

  Recruiting AIO-Studien-gGmbH · Oldenburg · NCT02622581

Related topics

Quick answers

How many Non Small Cell Lung Cancer Metastatic clinical trials are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in China (4 trials), United States (4 trials), Italy (3 trials), Denmark (2 trials), France (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 3: 2, Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →